Gene expression levels in normal donor B cell populations
| Up-regulated . | Fold change . | Down-regulated . | Fold change . | No change . |
|---|---|---|---|---|
| Tonsil IgD+CD38++ cells | ||||
| AICDA* | 4.9 | CR2 | 1.5 | TNFRSF7 (CD27) |
| APEX2* | 1.5 | CD40* | 1.5 | POL ζ (XPV) |
| CD38* | 4.4 | MBD4 | 1.7 | POLζ (Rev3) |
| CD80 (B7-1) | 1.5 | PMSL2 and PMSL3 (PMS) | 1.6-2.7 | RPA |
| EXO1* | 4.6 | POL μ | 2.2 | XPA |
| FEN1* | 2.1-2.2 | SMUG1 | 1.8 | XPC |
| MLH1* | 1.6 | XPD | ||
| MME (CD10)* | 9.6-13 | KU70 (XRCC6) | ||
| MSH2* | 1.6 | KU80 (XRCC5) | ||
| MSH3 | 1.5 | LIG4 | ||
| MSH5 | 1.4-1.8 | |||
| MSH6* | 1.5-1.9 | |||
| NEIL1* | 2.9 | |||
| OGG1* | 2.0 | |||
| PCNA* | 2.5 | |||
| POL θ* | 2.1-2.6 | |||
| RAD50* | 1.4 | |||
| RAD51* | 4.2-6.5 | |||
| UNG* | 1.8 | |||
| UNG2 | 1.7 | |||
| XRCC4* | 1.0-5.2 | |||
| Tonsil IgD−CD38++ cells | ||||
| AICDA* | 15.4 | CR2* | 1.7 | POL ζ (Rev3) |
| CD38* | 8.8 | ERCC1* | 1.5 | XPA |
| CD80 (B7-1)* | 1.8 | MSH4* | 1.5 | XPC |
| EXO1* | 6.4 | POL ι | 1.5 | XPD |
| FEN1* | 2.8-3.5 | POL μ | 3.3 | KU70 (XRCC6) |
| MLH1* | 1.8 | POL η | 2.7 | KU80 (XRCC5) |
| MME (CD10)* | 35-44 | LIG4 | ||
| MSH2* | 2.1 | |||
| PCNA* | 3.7 | |||
| POL θ* | 1.6-3.7 | |||
| RAD51* | 6.2-11.9 | |||
| RPA* | 1.8 | |||
| TNFRSF7 (CD27)* | 3.1 | |||
| UNG* | 3.0 |
| Up-regulated . | Fold change . | Down-regulated . | Fold change . | No change . |
|---|---|---|---|---|
| Tonsil IgD+CD38++ cells | ||||
| AICDA* | 4.9 | CR2 | 1.5 | TNFRSF7 (CD27) |
| APEX2* | 1.5 | CD40* | 1.5 | POL ζ (XPV) |
| CD38* | 4.4 | MBD4 | 1.7 | POLζ (Rev3) |
| CD80 (B7-1) | 1.5 | PMSL2 and PMSL3 (PMS) | 1.6-2.7 | RPA |
| EXO1* | 4.6 | POL μ | 2.2 | XPA |
| FEN1* | 2.1-2.2 | SMUG1 | 1.8 | XPC |
| MLH1* | 1.6 | XPD | ||
| MME (CD10)* | 9.6-13 | KU70 (XRCC6) | ||
| MSH2* | 1.6 | KU80 (XRCC5) | ||
| MSH3 | 1.5 | LIG4 | ||
| MSH5 | 1.4-1.8 | |||
| MSH6* | 1.5-1.9 | |||
| NEIL1* | 2.9 | |||
| OGG1* | 2.0 | |||
| PCNA* | 2.5 | |||
| POL θ* | 2.1-2.6 | |||
| RAD50* | 1.4 | |||
| RAD51* | 4.2-6.5 | |||
| UNG* | 1.8 | |||
| UNG2 | 1.7 | |||
| XRCC4* | 1.0-5.2 | |||
| Tonsil IgD−CD38++ cells | ||||
| AICDA* | 15.4 | CR2* | 1.7 | POL ζ (Rev3) |
| CD38* | 8.8 | ERCC1* | 1.5 | XPA |
| CD80 (B7-1)* | 1.8 | MSH4* | 1.5 | XPC |
| EXO1* | 6.4 | POL ι | 1.5 | XPD |
| FEN1* | 2.8-3.5 | POL μ | 3.3 | KU70 (XRCC6) |
| MLH1* | 1.8 | POL η | 2.7 | KU80 (XRCC5) |
| MME (CD10)* | 35-44 | LIG4 | ||
| MSH2* | 2.1 | |||
| PCNA* | 3.7 | |||
| POL θ* | 1.6-3.7 | |||
| RAD51* | 6.2-11.9 | |||
| RPA* | 1.8 | |||
| TNFRSF7 (CD27)* | 3.1 | |||
| UNG* | 3.0 |
Tonsil populations were determined from 3 individual normal donors.
Significant (P < .05) differences between tonsillar naive B cells (CD38−IgD+) versus activated naive/pre-GC founder cells (CD38++IgD+) or tonsillar GC cells (CD38++IgD−).